Dr Reddys Laboratories (RDY) Short term Debt (2016 - 2026)

Dr Reddys Laboratories' Short term Debt history runs 11 years deep, the most recent figure standing at $65.7 million for Q1 2026.

• In Q1 2026, Short term Debt fell 85.05% year-over-year to $65.7 million; the TTM figure through Mar 2026 stood at $65.7 million (down 85.05% YoY), while the FY2026 annual figure was $64.0 million, up 540.0% from the prior year.
• Short term Debt was $65.7 million for Q1 2026 at Dr Reddys Laboratories, down from $439.3 million in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $439.3 million in Q1 2025 to a low of $13.5 million in Q1 2022.
• Historically, Short term Debt has averaged $152.5 million across 5 years, with a median of $109.4 million in 2024.
• The sharpest annual moves came in 2023 and 2026: Short term Debt soared 332.08% in 2023, then slumped 85.05% in 2026.
• A 5-year view of Short term Debt shows it stood at $13.5 million in 2022, then jumped by 1268.08% to $185.0 million in 2023, then declined by 17.2% to $153.2 million in 2024, then surged by 186.77% to $439.3 million in 2025, then plunged by 85.05% to $65.7 million in 2026.
• The last three Short term Debt figures came in at $65.7 million (Q1 2026), $439.3 million (Q1 2025), and $153.2 million (Q1 2024), per Business Quant data.